Korea To Toughen Co-Bioequivalence Study System Amid Generic Quality Issue
Revised Pharma Act Clears First Parliamentary Hurdle
Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.
You may also be interested in...
A slew of recent manufacturing issues at several Korean pharma firms have prompted calls for improved quality control at and a change in the country's co-bioequivalence study system for generics.
After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.